24AA Preclinical Only
PEG-MGF
A PEGylated splice variant of IGF-1 studied for satellite cell activation and muscle regeneration; evidence is preclinical only, no human trials completed.
In Plain English: PEG-MGF is a synthetic version of Mechano Growth Factor — a naturally occurring signal your muscles release after mechanical stress or injury. The 'PEG' modification (polyethylene glycol) glues a protective polymer chain to the peptide, stretching its lifespan from about 5 minutes in the bloodstream to 48–72 hours. Scientists study it to understand how muscle stem cells (satellite cells) are recruited after damage, and whether the extended half-life makes it a practical tool for muscle-wasting research.
Research Maturity
Preclinical Only (204 PubMed papers on mechano growth factor / PEG-MGF+ Studies)
Quick Facts
Focus
Muscle Repair
Muscle Wasting Research
Route
SubQ
Origin
Endogenous IGF-1 splice variant (IGF-1Ec) expressed in mechanically stressed or injured muscle, heart, and nerve tissue. The synthetic PEGylated analog was developed for research use to address the ultra-short native half-life.
Mechanism
Binds MGF receptors distinct from the classical IGF-1 receptor, triggering satellite cell proliferation via MAPK/ERK1-2 and PKC/Nrf2 pathways. PEGylation (polyethylene glycol conjugation at Tyr-1) blocks proteolytic cleavage and increases hydrodynamic radius, reducing renal clearance. The E-peptide domain activates muscle progenitor cell division and inhibits premature differentiation independently of IGF-1R signaling.
Outcome
Satellite cell activation, muscle fibre cross-sectional area increase, protein synthesis upregulation, cardioprotection in ischemic models, osteoblast proliferation, and neuroprotection in aging animal models.
Safety Flags & Warnings
WADA Prohibited (S2)
No Human Clinical Trials
Anti-PEG Antibody Risk
IGF Pathway Cancer Concern
Satellite Cell Exhaustion
Research Chemical Only
Always consult a licensed physician. Research purposes only.
€12.5 / mg
